SOLARA ACTIVE PHARMA SCIENCES:

SOLARA ACTIVE PHARMA SCIENCES: Q1 CONS NET PROFIT 163M RUPEES VS 105M (YOY) SOLARA ACTIVE PHARMA SCIENCES: Q1 REVENUE 3.81B RUPEES VS 3.2B (YOY) Q1 EBITDA 619M RUPEES VS 570M (YOY) || Q1 EBITDA MARGIN 16.24% VS 17.87% (YOY) $SOLARA